Epalrestat, as the only AR inhibitor currently approved for clinical application, is used for the treatment of diabetic neuropathy by improving cell activity, and can be more specific and stable targeted inhibition of AR, with lasting efficacy and low side effects [25, 58]. The gene discussed is AR; the disease is diabetic neuropathy.